Clinical Trial: Phase II Single-arm Clinical Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery with High Risk of Recurrence

U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06851104) titled 'Phase II Single-arm Clinical Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery with High Risk of Recurrence' on Feb. 24.

Brief Summary: This study aims to evaluate the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma with combined high - risk recurrence factors.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma (HCC)

Intervention: DRUG: Cadonilimab (AK104)

Patients with hepatocellular carcinoma after curative hepatectomy would receive cadonilimab 10 mg/kg intravenous infusion (dissolved in 0.9% NaCl 250 mL, withi...